WIA
TGTX icon

Westview Investment Advisors’s TG Therapeutics TGTX Stock Holding History

Westview Investment Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.61M Sell
29,224
-37
-0.1% -$1.51K 0.79% 45
2026
Q1 		$972K Sell
29,261
-2,763
-9% -$82.3K 0.51% 52
2025
Q4 		$955K Buy
+32,024
New +$1.05M 0.45% 52

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Westview Investment Advisors's TGTX Position: Q2 2026 in Review

Westview Investment Advisors reduced its TG Therapeutics (TGTX) stake by 0.13% in Q2 2026, selling an estimated $1.51K and leaving 29,224 shares worth $1.61M. The position accounts for 0.79% of the portfolio, ranked #45.

Westview Investment Advisors first reported a position in TGTX in Q4 2025 and has held it in 3 quarters since. 428 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Westview Investment Advisors held 29,224 shares of TG Therapeutics worth $1.61M as of Q2 2026.
  • Westview Investment Advisors sold 37 TG Therapeutics shares in Q2 2026, an estimated $1.51K.
  • TG Therapeutics made up 0.79% of Westview Investment Advisors's portfolio in Q2 2026, its #45 holding.
  • Westview Investment Advisors first reported a position in TG Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 428 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Westview Investment Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.